Scientists from The Institute of Cancer Research, London, showed that the drug, NXP800, discovered at the same institute, slowed the growth of prostate cancer cells, including in cancer cells that ...

Scientists from The Institute of Cancer Research, London, showed that the drug, NXP800, discovered at the same institute, slowed the growth of prostate cancer cells, including in cancer cells that are ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The new urine test looks at 18 genes that are linked to high-risk prostate cancer. Previous research showed that MPS2 could ...

The pharma giant hosted its ninth annual Blue Jacket Fashion Show in collaboration with designer Frederick Anderson in New ...

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancerscreeningis highly accurate. The exciting new results, published in The Journal ...

The urine test, called MyProstateScore 2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. The researchers had previously demonstrated that the test was effective in ...

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about prostate cancer awareness and the FDA’s approval of a new pain medication. He also explains a ...

A new drug, NXP800, shows promise in treating hormone therapy-resistant prostate cancer by targeting the Heat Shock Factor 1 (HSF1) pathway, which supports cancer cell growth.